Dr. Daniel Stover is an Associate Professor of Internal Medicine in the Division of Medical Oncology and Department of Biomedical Informatics at Ohio State University Comprehensive Cancer Center. His research focus is clinical computational oncology – the application of computational approaches to leverage the immense available and potential data from tumor profiling to improve outcomes for patients with cancer. By working at the intersection of computational biology and clinical oncology, he seeks to advance novel technologies as a critical part of the future of how we will treat and cure cancer, including circulating tumor DNA and digital pathology.

Specifically, Dr. Stover's lab develops and implements 'big data' solutions to clinical challenges in breast cancer. As an early leader in the field of circulating tumor DNA 'liquid biopsy' in breast cancer, Dr. Stover has shepherded a low cost, minimally invasive test from research to clinical application in collaboration with the Broad Institute of Harvard & MIT, funded by a National Cancer Institute assay development grant. Dr. Stover and team have led the analysis of DNA and RNA sequencing of multiple large phase III clinical trials, driving forward understanding of new predictors of treatment benefit. More recently, his lab has advanced into digital pathology, using specialized high dimensional staining technologies and advanced modeling (including AI approaches) to interrogate millions of data points from a single tumor slide. This has led to provisional patents and industry collaborations to shepherd these discoveries to clinical diagnostics.

In parallel, he cares for patients with breast cancer at the Stefanie Spielman Comprehensive Breast Center and has been named a Castle Connolly Top Doctor for excellence in patient care. At OSUCCC, Dr. Stover supports collaborative research across the institution, serving as Director of Translational Breast Cancer Research and Principle Investigator of Total Cancer Care, a protocol that has enrolled >72,000 patients at the James Cancer Hospital to facilitate cancer research. Nationally, he is past Chair of the Membership Committee of ASCO, serves as Vice Chair (Correlative Science) of the Breast Committee of Alliance for Clinical Trials in Oncology, and is Co-Chair of the Alliance Standardized Translational 'Omics Resource (A-STOR).

Dr. Stover is a *cum laude* graduate of Princeton University and received his M.D. from Vanderbilt University where he was named to AOA Honor Medical Society. Dr. Stover did his residency in internal medicine at Vanderbilt University Medical Center and was selected to serve as the Hugh J. Morgan Chief Resident in Medicine. He completed his fellowship in Medical Oncology at the Dana-Farber Cancer Institute/Massachusetts General Hospital/Harvard Cancer Center program then completed postdoctoral research at Harvard Medical School in the lab of Joan Brugge, PhD and at the Broad Institute of Harvard and MIT. Dr. Stover was named a Fellow of the American Society of Clinical Oncology (FASCO) in 2023.